Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of 28-Day Oral Administration of AZD5069 Twice Daily in Patients With Bronchiectasis

NCT01255592 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01255592
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01255592 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of 28-Day Oral Administration of AZD5069 Twice Daily in Patients With Bronchiectasis
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2011
Completion date
February 29, 2012
Enrollment
83 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

bronchiectasis, lung disease, respiratory diseases